Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with non-invasive vulvar Paget's disease (a skin condition affecting the vulva) that is either a first diagnosis or has come back after surgery
- People who have had a biopsy confirming the condition within the last year
- People who are able to understand and agree to take part in the study
- People who are able to follow the study schedule and requirements
- Women who could become pregnant must be using an effective form of contraception
Who may not be able to join:
- People whose vulvar Paget's disease has grown deeper into the tissue (invasive form)
- People who also have an underlying gland-related cancer (adenocarcinoma)
- People who have a condition that makes their skin or body sensitive to light
- People who have used Imiquimod or Aldara 5% cream in the past 3 months
- People who have had light-based therapy (photodynamic therapy) to treat their Paget's disease in the past 3 months
- People who have used any medicines or products known to increase sensitivity to light in the past 3 months
- People who have taken part in another experimental drug study in the 30 days before this trial starts
- People who have a known allergy or sensitivity to methyl aminolevulinate or certain preserving ingredients (propyl p-hydroxybenzoate, cetostearyl alcohol, or methyl p-hydroxybenzoate)
- People with a known allergy to peanuts or soya, as one of the study medications (Metvixia®) contains peanut oil
- People who have a condition called Porphyria (a disorder affecting how the body processes certain substances)
- People who have applied steroid creams to the affected area in the past 3 months
- People who have an immune system condition such as HIV, or who have had an organ transplant
- People for whom regular follow-up appointments would not be possible due to psychological, family, social, or distance-related reasons
- People who are not legally able to consent to participation (confirm with trial site)
- People who are pregnant or currently breastfeeding
- People who do not wish to participate or do not agree to sign the consent form
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Laurent Mortier, MD,PhD, University Hospital, Lille
Phone: (0)3 20 44 48 68
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
disease control rate in 30% of patients included
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.